step up trial semaglutide 7·2 mg was modestly superior to placebo and 2·4 mg (#wegovy) for #WeightLoss in adults with obesity, while retaining a favourable risk–benefit profile. We recently had the lead author on the Efficacy of Oral Semaglutide: Overview

There is no approved or investigational GLP-2 weight-loss medication

The realistic timeline, based on the current trial schedule: Q2-Q3 2026 TRIUMPH-1 and TRIUMPH-2 primary readouts

Saxenda, on the other hand, is used for long-term weight management by adults and for the adolescents who meet the certain BMI rate, thus it can be available for the people who want to lose weight

The out-of-pocket cost burden remains a significant variable, influencing formulary tier placement and overall market penetration across different healthcare systems

This designation speeds up the drug submission and review process with the FDA